Clinical Trials Logo

Esophageal Neoplasms clinical trials

View clinical trials related to Esophageal Neoplasms.

Filter by:

NCT ID: NCT05303740 Completed - Clinical trials for Esophageal Neoplasms

Anlotinib Retrospective Study for Esophageal Cancer

Start date: January 1, 2019
Phase:
Study type: Observational

The efficacy of anlotinib in the treatment of esophageal cancer has been confirmed. The purpose of this study was to retrospectively observe the efficacy and safety of anlotinib in the first and second line of advanced esophageal cancer in the real world.

NCT ID: NCT05194371 Completed - Clinical trials for Esophageal Neoplasms

Report of the Survival Outcomes of Patients With Esophageal Cancer After Definitive Radiotherapy in China

Start date: June 1, 2021
Phase:
Study type: Observational

In this study, data of esophageal cancer patients undergoing definitive radiotherapy in 14 institutions from various provinces in China were evaluated to help strengthen confidence in anti-cancer, including rehabilitation, economic burden, and quality of life.

NCT ID: NCT05088304 Completed - Malnutrition Clinical Trials

GLIM-defined Malnutrition Criteria for Postoperative Outcomes in Patients With Esophagogastric Cancer

Start date: September 1, 2015
Phase:
Study type: Observational

The present study aims to investigate the prognostic value of preoperative fat-free mass index for postoperative outcomes in patients undergoing esophagogastric cancer surgery, and to explore the role of the FFMI in the Global Leadership Initiative on Malnutrition (GLIM) criteria.

NCT ID: NCT05069766 Completed - Clinical trials for Esophagus Cancer, Adenocarcinoma

Preoperative Marking of the Oral Resection Margin in Esophageal Cancer With a Surgical Fiducial Marker - First Experiences

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

This study aims to evaluate if BioXmark™, a surgical marker, may efficiently and safely be used to preoperatively mark the proximal and distal resection line 5 cm proximal and distal to the tumor margin of gastroesophageal-junction adenocarcinoma (GEJ AC). Furthermore, to determine if placing the resection margin according to the resection margin defined by BioXmark™ is superior to the current standard of a proximal resection line estimation by the individual surgeon based on the intraoperative findings.

NCT ID: NCT05039983 Completed - Clinical trials for Esophageal Obstruction

Study of Epigallocatechin-3-gallate (EGCG) for Supportive and Symptomatic Management in Patients With Esophageal Cancer

Start date: August 20, 2021
Phase: Phase 1
Study type: Interventional

The main symptom of patients with advanced esophageal cancer is eating obstruction. In clinical practice, patients need to wait for a long time before anti-tumor treatment, which will lead to a rapid decline in the quality of life and nutritional status of patients, and severe patients sometimes need to place nasointestinal feeding tubes or endoscopic stents. EGCG has been shown to have antioxidant, anti-inflammatory and anti-tumor effects . The complex effects of EGCG may improve esophageal obstruction during the waiting period before antineoplastic therapy. The purpose of this phase I study was to explore the safety, recommended dose and preliminary efficacy of EGCG solution in the treatment of esophageal obstruction.

NCT ID: NCT04994548 Completed - Cirrhosis Clinical Trials

Endoscopic Resection of Early Esophageal Tumors in the Context of Cirrhosis or Portal Hypertension

Start date: January 1, 2005
Phase:
Study type: Observational

Cirrhotic patients may be at high risk for esophageal cancer. Endoscopic resection is the standard treatment for superficial tumors. However, cirrhosis might be associated with upper gastrointestinal bleeding, particularly in case of portal hypertension or coagulopathy. This study aims to assess safety, efficacy and methods to prevent potential complications in cirrhosis or portal hypertension context for esophageal endoscopic resection. This retrospective multicentric French-Belgian study includes all consecutive patients with cirrhosis or portal hypertension who underwent esophageal endoscopic resection from January 2005 to 2021.

NCT ID: NCT04973046 Completed - Clinical trials for Esophageal Neoplasms

Tissue Oxygen Saturation for Esophagectomy

Start date: November 1, 2020
Phase:
Study type: Observational

Tissue oxygen saturation monitoring was a useful indicator of blood flow insufficiency in the gastric tube leading to anastomotic leakage during radical esophagectomy.

NCT ID: NCT04958044 Completed - Esophageal Cancer Clinical Trials

Endoscopic Assisted Calcium Electroporation in Esophageal Cancer

Start date: May 25, 2021
Phase: Phase 1
Study type: Interventional

In this pilot study, patients with non-curable esophageal cancer will be treated with endoscopic assisted calcium electroporation (CaEP). CaEP is a novel cancer treatment where intratumoral injection with calcium is combined with locally applied electrical pulses, in order to increase calcium influx which leads to tumor necrosis. It is hypothesized that: - Endoscopic assisted CaEP is a safe and feasible procedure in patients with non-curable esophageal cancer - CaEP debulks the tumor, facilitating the patient's ability to eat and drink In this single-arm pilot study, eight patients will be treated.

NCT ID: NCT04936399 Completed - Clinical trials for Esophageal Squamous Cell Carcinoma

A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom

Start date: June 25, 2020
Phase:
Study type: Observational

This purpose of this observational study is to review medical chart and patient survey data collection within an early access to medicines scheme (EAMS) program. Participant who are eligible, provide consent and enroll into the squamous cell oesophageal cancer EAMS to receive Nivolumab will be included in this study.

NCT ID: NCT04822103 Completed - Esophageal Cancer Clinical Trials

A Real-World Study of Immune Checkpoint Inhibitors and Chemotherapy for Advanced Esophageal Cancer

Start date: January 1, 2021
Phase:
Study type: Observational

The role of preoperative chemotherapy as standard therapy is well-established for advanced esophageal cancer. Immunotherapeutic agents such as Immune checkpoint inhibitors has been shown to improve objective response rate in solid tumors. However, there is a paucity of data regarding the efficacy and safety of preoperative immunotherapy plus chemotherapy in esophageal cancer patients in real-world practice. This study set out to investigate whether the combination of preoperative chemotherapy and immune checkpoint inhibitors is beneficial to improve the objective response rate as well as the pathological complete response rate in a real-world scenario.